Iain Kilty

Sitryx Therapeutics Ltd. Focuses on regulating cell metabolism to develop disease-modifying therapeutics in immuno-oncology and immuno-inflammation. It treats cancer and inflammatory conditions by targeting the metabolism of immune cells. The company was founded by Houman Ashrafian, Paul-Peter Tak, Luke O'Neill, Jonathan Powell, Jeff Rathmell and Michael Rosenblum and is headquartered in London, the United Kingdom.

SV Health Investors LLP (SV Health Investors) is a venture capital firm founded in 1994 by Peter McPartland. The firm is headquartered in London.

Octagon Therapeutics, Inc. engages in the research and development of medicines based on novel metabolic targets in disease-causing bacteria, lymphocytes, and cancer cells. It develops a discovery platform that identifies novel therapeutic targets and small molecule inhibitors that are invisible in standard culture conditions. The company was founded by Fred Ausubel, Isaac Stoner, and Shen Yu in 2016 and is headquartered in Allston, MA.

Quench Bio, Inc. develops therapies targeting innate immune pathways to treat life-threatening auto-immune and inflammatory diseases. The company was founded by Mark J. Tebbe, Mike Nolan, and Arturo Zychlinsky and is headquartered in Cambridge, MA.